FDA BRUDAC panel backs Agile Therapeutics’ Twirla contraceptive patch
Category: #health  By Mateen Dalal  Date: 2019-10-31
  • share
  • Twitter
  • Facebook
  • LinkedIn

FDA BRUDAC panel backs Agile Therapeutics’ Twirla contraceptive patch

Agile Therapeutics, Inc., a renowned New Jersey based women’s healthcare and pharmaceutical company, has reportedly announced the positive outcome of a recent U.S. FDA Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) meeting held to discuss Agile’s New Drug Application (NDA) for Twirla® (AG200-15), the company’s lead candidate.

Twirla is the company’s investigational combined-hormonal contraceptive (CHC) patch, which is made up of levonorgestrel (LNG), a progestin, and ethinyl estradiol (EE), an estrogen. The BRUDAC meeting saw Twirla receive a majority vote; 14 to one, with one abstention, over the assessment that the benefits of the candidate in prevention of pregnancy far outweigh the overall risk.

The Chief Executive Officer and Chairman of Agile Therapeutics, Al Altomari stated that the company is pleased that the FDA committee voted in favor of the company’s investigational product candidate. The favorable vote represents an integral milestone towards the company’s journey of delivering a novel, innovative contraceptive for women.

Altomari further added that the company now looks forward to continuing its dialogue with the Food and Drug Administration regarding the crucial data presented at the meeting and working for the potential FDA approval of the product.

According to reports, the Twirla contraceptive patch is based upon the company’s proprietary transdermal patch technology, named Skinfusion®. The Skinfusion technology has been specifically designed to facilitate drug delivery through the patient’s skin.

The contraceptive patch is designed to be applied to the skin once a week for a period of three weeks, which would be followed by a week-long period without the patch. Agile has completed the product’s Phase 3 clinical trial and is currently seeking to obtain a regulatory approval in the United States after the New Drug Application resubmission.

Agile Therapeutics resubmitted the NDA for the CHC patch back on 16th May 2019. The FDA takes the BRUDAC’s non-binding vote into consideration as a part of the NDA evaluation.

The FDA has now assigned November 16, 2019 as the Prescription Drug User Fee Act (PDUFA) goal date for completion of the Twirla NDA review.
 

Source credit: https://ir.agiletherapeutics.com/news-releases/news-release-details/agile-therapeutics-announces-favorable-outcome-fda-advisory

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

TPG Rise Climate Fund raises $5.4Bn to support new climate solutions
TPG Rise Climate Fund raises $5.4Bn to support new climate solutions
By Mateen Dalal

TPG Rise Climate Fund, the climate investing fund of TPG’s global impact investing platform TPG Rise, has recently raised its first close of $5.4 billion, bringing together an exclusive blend of funding from some of the top institutional invest...

Baby nutrition firm ByHeart nabs $90Mn in Series B funding round
Baby nutrition firm ByHeart nabs $90Mn in Series B funding round
By Mateen Dalal

ByHeart, a fully integrated infant nutrition company, has reportedly secured $90 million in Series B funding which the company plans to use for the launch of its baby formula and support the development of its pipeline of nutrition items for chi...

UAE extends travel ban for Indians amid strict COVID-19 guidelines
UAE extends travel ban for Indians amid strict COVID-19 guidelines
By Mateen Dalal

United Arab Emirates (UAE) has reportedly extended travel ban for individuals travelling from India and several other south Asian countries on the pretext of COVID-19 guidelines. As reported by Etihad Airlines, the ban will be followed till 31st July...